CN105367573B - AGT protein inhibitors, its preparation method and application - Google Patents
AGT protein inhibitors, its preparation method and application Download PDFInfo
- Publication number
- CN105367573B CN105367573B CN201510674275.8A CN201510674275A CN105367573B CN 105367573 B CN105367573 B CN 105367573B CN 201510674275 A CN201510674275 A CN 201510674275A CN 105367573 B CN105367573 B CN 105367573B
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- formula
- agt
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- WVDDGKGOMKODPV-UHFFFAOYSA-N OCc1ccccc1 Chemical compound OCc1ccccc1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of new tumour cell targeting AGT protein inhibitors, its preparation method and application with high activity.The inhibitor is with as led to the compound shown in formula (I) structure：The compound specific can be activated under low oxygen conditions, and nitryl group is reduced to amino group, O of the generation with AGT inhibitory activity6Benzyl guanine derivative, so as to realize acting on tumour cell and playing AGT inhibitory action for targeting, reaches the purpose for improving tumour cell to anticancer alkylating agent sensitiveness.In addition, compared with existing AGT protein inhibitors, also active higher, the water-soluble stronger advantage of the compound.
Description
Technical field
The present invention relates to pharmaceutical field, specifically, be related to a kind of new AGT protein inhibitors, its preparation method and
Using.
Background technology
O6- alkylguanine-DNA alkyl transferase (AGT) is a kind of DNA repair protein, and it can be to being damaged by alkanisation
The DNA molecular of wound is repaired, by alkylguanine O6The alkyl group combined on position is transferred to activity itself position from guanine
On the cysteine residues of point, so as to protect DNA not damaged by alkylating agent.Research shows, guanine O6Methyl, 2- on position
The groups such as chloroethyl, benzyl and pyridyl oxo butyl can be removed by AGT.However, facing in alkylating agents antineoplastic
In bed application, AGT in tumour cell can cause tumour cell to alkylating agents by repairing DNA damage caused by alkylating agent
Cancer therapy drug produces drug resistance, ultimately results in chemotherapy failure.For example, for difunctional alkylating agent Dichloroethyl nitroso ureas
(BCNU, BCNU), AGT can be by repairing O caused by BCNU6- chloroethyl guanine intermediate and blocking dna stock between hand over
The formation of connection, causes tumour cell to produce drug resistance to BCNU.Therefore, effective AGT inhibitor is designed and developed and by itself and alkane
Agent kind anti-cancer drugs thing is united and applied in chemotherapy of tumors, sensitiveness, reduction resistance for enhancing tumour cell to chemotherapeutics
Property, improve chemotherapy effect it is significant.
O6- benzyl guanine is current AGT inhibitor most widely used in clinical test, can be complete in 15 minutes
The full AGT activity suppressed in Human colorectal carcinoma HT29 cells, while improving tumour cell to the quick of CCNU
Perception.But, due to O6The problem of there is limited activity, poorly water-soluble in-benzyl guanine, especially without tumour cell target
Tropism, therefore fail clinically to be widely used.Research shows, O6- benzyl guanine is suppressing tumour cell AGT work
The content of AGT in normal cell is greatly reduced while property, so as to cause the bone marrow suppression toxicity of chemotherapeutics significantly to increase
By force, chemotherapy failure is ultimately resulted in.Therefore, the new A GT inhibitor with tumour cell targeting is designed and developed, can be special
Tumour cell is acted on different in naturely and AGT inhibitory activity is played, and is to improve sensitivity of tumor cells, while protecting normal cell not
Damaged by chemotherapeutics, so as to realize the important channel of the therapeutic strategy of high-efficiency low-toxicity.
The content of the invention
It is an object of the invention to provide a kind of new tumour cell targeting AGT protein inhibitors with high activity,
Its preparation method and application.
Because the fast-growth of tumour cell can result in inside tumor anoxic, therefore, hypoxemia is present in solid tumor
A kind of universal phenomenon.The present invention is using this feature of tumor hypoxia, and the AGT albumen that having synthesized a class, there is hypoxemia to activate suppresses
Agent, such compound can not be activated in the normal tissue, thus will not suppress the activity of the AGT in normal cell；But can
Specifically it is activated under the conditions of hypoxia in tumor cells, produces the compound with AGT inhibitory activity.Therefore, such chemical combination
The AGT activity that thing specific can suppress tumour cell, improves to targeting sensitiveness of the tumour cell to chemotherapeutics, from
And it is united and applied in chemotherapy of tumors with alkylating agents antineoplastic.
In order to realize the object of the invention, a kind of AGT protein inhibitors that characteristic is activated with hypoxemia that the present invention is provided, institute
It is with as led to the compound shown in formula (I) structure to state inhibitor：
Preferably, the inhibitor is O6- (2- nitrobenzyls) -9 hydrogen-guanine (compound 1), O6- (3- nitrobenzyls
Base) -9 hydrogen-guanine (compound 2), O6- (4- nitrobenzyls) -9 hydrogen-guanine (compound 3)：
The present invention also provides the preparation method of the AGT protein inhibitors, comprises the following steps：
1) 2- amido-6-chloropurines (a) and 1- crassitudes reaction generation compound (b), i.e. 1- (2- amino -9- hydrogen -
Purine -6-) -1- crassitude chlorides；
2) formula (II) compound and compound (b) the reaction generation inhibitor.
Wherein, the structural formula of compound (b) is as follows：
The general structure of formula (II) compound is as follows, and nitro is located at ortho position, meta or para position：
Above-mentioned course of reaction is as follows：
Foregoing method, step 1) be specially：2- amido-6-chloropurines (a) are dissolved in organic solvent, 1- methyl pyrroles are added
Alkane is coughed up, stirring reaction, reaction generation compound (b), reaction terminates to add acetone in backward solution and continues stirring to compound
(b) precipitate completely, filter and by the solid being collected into, washed with ether 2 times, be dried in vacuo, obtain dry compound (b).
Step 1) in the mol ratio of 2- amido-6-chloropurines and 1- crassitudes be 1:1-4, preferably 1:2-3；It is described to have
Machine solvent is DMF or dimethyl sulfoxide (DMSO), preferably DMF, and consumption of organic solvent is by 2-
Amido-6-chloropurine 1mmol is counted, and uses organic solvent 10-15mL；Reaction temperature is controlled at 20-40 DEG C, preferably 25-35 DEG C；Instead
It is 12-24 hours, preferably 16-20 hours between seasonable.
Foregoing method, step 2) be specially：Formula (II) compound is dissolved in organic solvent, step 1 is added) obtain
Compound (b), sodium hydride and dimethyl aminopyridine, the stirring reaction under inert gas shielding, reaction add ice second after terminating
Aqueous acid adds saturated ammonium chloride and ethyl acetate by volume 1 to neutralize excessive sodium hydride to pH value of solution=7, then：1
The mixed liquor of composition is extracted, and the ethyl acetate layer after extraction is washed with deionized 2 times again, vacuum drying, obtains formula (I)
The crude product of compound, crude product purified by silica gel column chromatography is purified, and produces the inhibitor.
Step 2) in dimethylamino naphthyridine, compound (b), the mol ratio of formula (II) compound and sodium hydride be 1:6-12:
10-50:30-60, preferably 1:8-10:20-30:40-50；The organic solvent is that N,N-dimethylformamide or dimethyl are sub-
Sulfone, preferably DMF, consumption of organic solvent are based on compound (b) 1mmol, to use organic solvent 10-15mL；
Reaction temperature is controlled at 20-35 DEG C, preferably 25-30 DEG C；Reaction time is 3-6 hours, preferably 4-5 hours.
Preferably, step 2) in silica gel column chromatography when purifying eluant, eluent used for methanol and dichloromethane mixing
Liquid, using the method for gradient elution, the volume ratio of methanol and dichloromethane is by 1 in mixed liquor:50 gradually become 1:10.
The present invention has advantages below with the AGT protein inhibitors that hypoxemia activates characteristic：
(1) formula (I) compound that the present invention is provided specific can be activated under low oxygen conditions, and nitryl group is gone back
Originally it was amino group, O of the generation with AGT inhibitory activity6- benzyl guanine derivative, i.e. O6- (aminobenzyl) -9 hydrogen-bird is fast
Purine, so as to realize acting on tumour cell and playing AGT inhibitory action for targeting, reaches raising tumour cell to anticancer alkanisation
The purpose of agent sensitiveness.
(2) extracorporeal anti-tumor screening test is carried out to formula (I) compound, as a result shown, under low oxygen conditions, formula (I) is changed
Compound and BCNU drug combinations, under low oxygen conditions, to nasopharyngeal carcinoma cell KB, human cervical carcinoma cell HelaS3, human brain neuroglia
Matter oncocyte SF763, Human Prostate Cancer Cells DU145, human colon cancer cell HT29 cells and lymphoma cell Raji have bright
Aobvious inhibitory action；And under aerobic conditions, formula (I) compound and BCNU drug combinations, the suppression to above-mentioned tumour cell are made
With unobvious.Therefore, formula (I) compound has good targeting, can significantly improve tumour cell anti-to alkylating agents swollen
The sensitiveness of tumor medicine, the targeting combined chemotherapy available for tumour.
(3) compared with existing AGT protein inhibitors, formula (I) compound is also active higher, water-soluble stronger
Advantage.
Embodiment
Following examples are used to illustrate the present invention, but are not limited to the scope of the present invention.If not specializing, embodiment
In the conventional meanses that are well known to those skilled in the art of used technological means, it is raw materials used to be commercial goods.
The general structure of formula (II) compound being related in following examples is as follows：
Wherein, corresponding compound is respectively (c), (d), (e) when nitro is located at ortho position, meta or para position.
The structural formula of the compound 1, compound 2 and the compound 3 that are related in following examples is as follows：
The O of embodiment 16The synthesis of-(2- nitrobenzyls) -9 hydrogen-guanine (compound 1)
(1) synthesis of 1- (2- amino -9- hydrogen-purine -6-) -1- crassitude chlorides (b)
356mg (2.1mmol) 2- amido-6-chloropurines (a) are dissolved in 30mL DMFs, added
0.33mL (6.2mmol) 1- crassitudes, reactant whole reaction system stirring reaction under the conditions of 25 DEG C after all dissolving
17 hours, reaction added 2mL acetone and continues stirring to complete precipitation in the solution after terminating, filtering collects solid through ether
Washing 2 times, vacuum drying, obtains compound (b) 300mg (1.18mmol), yield 56%.
The feature of compound (b) is as follows：
UVλ：289nm；
IR (KBr compressing tablets) v/cm-1：3445.4 (N-H), 3274.9 (NH2), 2974.9 (C-H), 1719.3 (C=N),
1552.7 (C=C)；
1H-NMR(DMSO-d6)δ：1.73(m,2H,CH2), 2.90 (s, 3H, CH3), 3.24 (m, 2H, CH2), 6.99 (s,
2H,NH2), 8.57 (s, 1H, CH), 11.00 (s, 1H, NH)；
ESI-MS：255[M+H]+。
(2) synthesis of compound 1
524mg (3.42mmol) compound (c) is dissolved in 15mL DMFs, 147mg is sequentially added
Obtained compound (b) and 17mg in (6.11mmol) sodium hydride (NaH), 300mg (1.18mmol) step (1)
(0.14mmol) dimethyl aminopyridine solid, all dissolving after under argon gas protection in 25 DEG C of environment stirring reactions 4 hours.Instead
The glacial acetic acid aqueous solution is added after should terminating to neutralize excessive sodium hydride to pH value of solution=7, saturated ammonium chloride and second is then added
Acetoacetic ester is 1 according to volume ratio:The mixed liquor of 1 composition is extracted, and the ethyl acetate layer after extraction is washed with deionized 2 again
Secondary, vacuum drying obtains the crude product of compound 1.Crude product purified by silica gel column chromatography is purified, eluant, eluent is methanol and dichloro
Methane, using the method for gradient elution, from ethanol/methylene (v/v) 1:50 gradually become 1:10, obtain compound 1
220mg (0.77mmol), yield 65%.
The feature of compound 1 is as follows：
UVλ：239nm；
IR (KBr compressing tablets) v/cm-1：3412.6 (N-H), 2924.4 (- CH2-), 1592.5 (C=C), 1460.8 (C=N)；
1397.5(C-O-C)；
1H-NMR(DMSO-d6)δ：5.16(s,2H,CH2), 6.99 (s, 2H, NH2), 7.62-8.01 (m, 4H, C6H4),
8.57 (s, 1H, CH), 11.00 (s, 1H, NH)；
ESI-MS：287[M+H]+。
The O of embodiment 26The synthesis of-(2- nitrobenzyls) -9 hydrogen-guanine (compound 1)
(1) synthesis of 1- (2- amino -9- hydrogen-purine -6-) -1- crassitude chlorides (b)
322mg (1.9mmol) 2- amido-6-chloropurines are dissolved in 27mL DMFs, 0.30mL is added
(5.6mmol) 1- crassitudes, reactant whole reaction system stirring reaction 16 hours under the conditions of 27 DEG C after all dissolving,
Reaction adds 2mL acetone and continues stirring to complete precipitation in the solution after terminating, filtering is collected solid and washed 2 times through ether,
Vacuum drying, obtains compound (b) 278mg (1.09mmol), yield 57%.
The feature of compound (b) is as follows：
UVλ：289nm；
IR (KBr compressing tablets) v/cm-1：3446.5 (N-H), 3287.1 (NH2), 2981.5 (C-H), 1723.9 (C=N),
1559.6 (C=C)；
1H-NMR(DMSO-d6)δ：1.79(m,2H,CH2), 3.12 (s, 3H, CH3), 3.37 (m, 2H, CH2), 6.97 (s,
2H,NH2), 8.62 (s, 1H, CH), 11.09 (s, 1H, NH)；
ESI-MS：255[M+H]+。
(2) synthesis of compound 1
507mg (3.31mmol) compound (c) is dissolved in 15mL DMFs, 142mg is sequentially added
Obtained compound (b) and 16mg in (5.92mmol) sodium hydride (NaH), 278mg (1.09mmol) step (1)
(0.13mmol) dimethyl aminopyridine solid, all dissolving after under argon gas protection in 26 DEG C of environment stirring reactions 5 hours.Instead
The glacial acetic acid aqueous solution is added after should terminating to neutralize excessive sodium hydride to pH value of solution=7, saturated ammonium chloride and second is then added
Acetoacetic ester is 1 according to volume ratio:The mixed liquor of 1 composition is extracted, and the ethyl acetate layer after extraction is washed with deionized 2 again
Secondary, vacuum drying obtains the crude product of compound 1.Crude product purified by silica gel column chromatography is purified, eluant, eluent is methanol and dichloro
Methane, using the method for gradient elution, from ethanol/methylene (v/v) 1:50 gradually become 1:10, obtain compound 1
194mg (0.68mmol), yield 62%.
The feature of compound 1 is as follows：
UVλ：239nm；
IR (KBr compressing tablets) v/cm-1：3341.1 (N-H), 1671.1 (C=C), 1474.6 (C=N), 1262.7 (C-O-C)；
1H-NMR(DMSO-d6)δ：5.35(s,2H,CH2), 6.31 (s, 2H, NH2), 7.73-8.13 (m, 4H, C6H4),
8.87 (s, 1H, CH), 11.26 (s, 1H, NH)；
ESI-MS：287[M+H]+。
The O of embodiment 36The synthesis of-(3- nitrobenzyls) -9 hydrogen-guanine (compound 2)
(1) synthesis of 1- (2- amino -9- hydrogen-purine -6-) -1- crassitude chlorides (b)
390mg (2.3mmol) 2- amido-6-chloropurines are dissolved in 30mL DMFs, 0.36mL is added
(6.8mmol) 1- crassitudes, reactant whole reaction system stirring reaction 19 hours under the conditions of 27 DEG C after all dissolving,
Reaction adds 2mL acetone and continues stirring to complete precipitation in the solution after terminating, filtering is collected solid and washed 2 times through ether,
Vacuum drying, obtains compound (b) 310mg (1.22mmol), yield 53%.
The feature of compound (b) is as follows：
UVλ：289nm；
IR (KBr compressing tablets) v/cm-1：3455.9 (N-H), 3289.8 (NH2), 2989.7 (C-H), 1744.7 (C=N),
1574.3 (C=C)；
1H-NMR(DMSO-d6)δ：1.81(m,2H,CH2), 2.85 (s, 3H, CH3), 3.10 (m, 2H, CH2), 6.85 (s,
2H,NH2), 8.69 (s, 1H, CH), 11.12 (s, 1H, NH)；
ESI-MS：255[M+H]+。
(2) synthesis of compound 2
583mg (3.81mmol) compound (d) is dissolved in 15mL DMFs, 163mg is sequentially added
Obtained compound (b) and 18mg in (6.79mmol) sodium hydride (NaH), 310mg (1.22mmol) step (1)
(0.15mmol) dimethyl aminopyridine solid, all dissolving after under argon gas protection in 27 DEG C of environment stirring reactions 4 hours.Instead
The glacial acetic acid aqueous solution is added after should terminating to neutralize excessive sodium hydride to pH value of solution=7, saturated ammonium chloride and second is then added
Acetoacetic ester is 1 according to volume ratio:The mixed liquor of 1 composition is extracted, and the ethyl acetate layer after extraction is washed with deionized 2 again
Secondary, vacuum drying obtains the crude product of compound 2.Crude product purified by silica gel column chromatography is purified, eluant, eluent is methanol and dichloro
Methane, using the method for gradient elution, from ethanol/methylene (v/v) 1:50 gradually become 1:10, obtain compound 2
232mg (0.81mmol), yield 66%.
The feature of compound 2 is as follows：
UVλ：262nm；
IR (KBr compressing tablets) v/cm-1：3400.6 (N-H), 2924.9 (- CH2-), 1529.5 (N=O), 1403.2 (C=N),
1141.8(C-N)；
1H-NMR(DMSO-d6)δ：5.22(s,2H,CH2), 6.87 (s, 2H, NH2), 7.86-8.25 (m, 4H, C6H4),
8.32 (s, 1H, CH), 11.26 (s, 1H, NH)；
ESI-MS：287[M+H]+。
The O of embodiment 46The synthesis of-(3- nitrobenzyls) -9 hydrogen-guanine (compound 2)
(1) synthesis of 1- (2- amino -9- hydrogen-purine -6-) -1- crassitude chlorides (b)
424mg (2.5mmol) 2- amido-6-chloropurines are dissolved in 30mL DMFs, 0.39mL is added
(7.4mmol) 1- crassitudes, reactant whole reaction system stirring reaction 20 hours under the conditions of 28 DEG C after all dissolving,
Reaction adds 2mL acetone and continues stirring to complete precipitation in the solution after terminating, filtering is collected solid and washed 2 times through ether,
Vacuum drying, obtains compound (b) 328mg (1.29mmol), yield 52%.
The feature of compound (b) is as follows：
UVλ：289nm；
IR (KBr compressing tablets) v/cm-1：3457.8 (N-H), 3290.3 (NH2), 2977.6 (C-H), 1751.2 (C=N),
1579.2 (C=C)；
1H-NMR(DMSO-d6)δ：1.84(m,2H,CH2), 2.87 (s, 3H, CH3), 3.14 (m, 2H, CH2), 6.79 (s,
2H,NH2), 8.61 (s, 1H, CH), 11.07 (s, 1H, NH)；
ESI-MS：255[M+H]+。
(2) synthesis of compound 2
625mg (4.08mmol) compound (d) is dissolved in 15mL DMFs, 175mg is sequentially added
Obtained compound (b) and 20mg in (7.28mmol) sodium hydride (NaH), 328mg (1.29mmol) step (1)
(0.16mmol) dimethyl aminopyridine solid, all dissolving after under argon gas protection in 25 DEG C of environment stirring reactions 5 hours.Instead
The glacial acetic acid aqueous solution is added after should terminating to neutralize excessive sodium hydride to pH value of solution=7, saturated ammonium chloride and second is then added
Acetoacetic ester is 1 according to volume ratio:The mixed liquor of 1 composition is extracted, and the ethyl acetate layer after extraction is washed with deionized 2 again
Secondary, vacuum drying obtains the crude product of compound 2.Crude product purified by silica gel column chromatography is purified, eluant, eluent is methanol and dichloro
Methane, using the method for gradient elution, from ethanol/methylene (v/v) 1:50 gradually become 1:10, obtain compound 2
277mg (0.97mmol), yield 75%.
The feature of compound 2 is as follows：
UVλ：262nm；
IR (KBr compressing tablets) v/cm-1：3406.1 (N-H), 2782.8 (- CH2-), 1632.7 (C=C), 1273.9 (C-O-
C), 1085.2 (C-N)；
1H-NMR(DMSO-d6)δ：5.33(s,2H,CH2), 6.28 (s, 2H, NH2), 7.51-8.03 (m, 4H, C6H4),
8.81 (s, 1H, CH), 11.42 (s, 1H, NH)；
ESI-MS：287[M+H]+。
The O of embodiment 56The synthesis of-(4- nitrobenzyls) -9 hydrogen-guanine (compound 3)
(1) synthesis of 1- (2- amino -9- hydrogen-purine -6-) -1- crassitude chlorides (b)
339mg (2.0mmol) 2- amido-6-chloropurines are dissolved in 30mL DMFs, 0.31mL is added
(5.9mmol) 1- crassitudes, reactant whole reaction system stirring reaction 18 hours under the conditions of 29 DEG C after all dissolving,
Reaction adds 2mL acetone and continues stirring to complete precipitation in the solution after terminating, filtering is collected solid and washed 2 times through ether,
Vacuum drying, obtains compound (b) 288mg (1.13mmol), yield 57%.
The feature of compound (b) is as follows：
UVλ：289nm；
IR (KBr compressing tablets) v/cm-1：3434.7 (N-H), 3225,3 (NH2), 2957.4 (C-H), 1733.5 (C=N),
1523.5 (C=C)；
1H-NMR(DMSO-d6)δ：1.62(m,2H,CH2), 3.14 (s, 3H, CH3), 3.31 (m, 2H, CH2), 7.01 (s,
2H,NH2), 8.49 (s, 1H, CH), 10.97 (s, 1H, NH)；
ESI-MS：255[M+H]+。
(2) synthesis of compound 3
545mg (3.56mmol) compound (e) is dissolved in 15mL DMFs, 153mg is sequentially added
Obtained compound (b) and 17mg in (6.37mmol) sodium hydride (NaH), 288mg (1.13mmol) step (1)
(0.14mmol) dimethyl aminopyridine solid, all dissolving after under argon gas protection in 26 DEG C of environment stirring reactions 4 hours.Instead
The glacial acetic acid aqueous solution is added after should terminating to neutralize excessive sodium hydride to pH value of solution=7, saturated ammonium chloride and second is then added
Acetoacetic ester is 1 according to volume ratio:The mixed liquor of 1 composition is extracted, and the ethyl acetate layer after extraction is washed with deionized 2 again
Secondary, vacuum drying obtains the crude product of compound 3.Crude product purified by silica gel column chromatography is purified, eluant, eluent is methanol and dichloro
Methane, using the method for gradient elution, from ethanol/methylene (v/v) 1:50 gradually become 1:10, obtain compound 3
183mg (0.64mmol), yield 57%.
The feature of compound 3 is as follows：
UVλ：272nm；
IR (KBr compressing tablets) v/cm-1：3389.4 (N-H), 1524.3 (N=O), 1415.3 (C=N), 1347.6 (C-O-C),
1014.1(C-N)；
1H-NMR(DMSO-d6)δ：5.29(s,2H,CH2), 6.74 (s, 2H, NH2), 7.62-8.19 (m, 4H, C6H4),
8.45 (s, 1H, CH), 11.17 (s, 1H, NH)；
ESI-MS：287[M+H]+。
The O of embodiment 66The synthesis of-(4- nitrobenzyls) -9 hydrogen-guanine (compound 3)
(1) synthesis of 1- (2- amino -9- hydrogen-purine -6-) -1- crassitude chlorides (b).
305mg (1.8mmol) 2- amido-6-chloropurines are dissolved in 26mL DMFs, 0.28mL is added
(5.3mmol) 1- crassitudes, reactant whole reaction system stirring reaction 16 hours under the conditions of 32 DEG C after all dissolving,
Reaction adds 2mL acetone and continues stirring to complete precipitation in the solution after terminating, filtering is collected solid and washed 2 times through ether,
Vacuum drying, obtains compound (b) 260mg (1.02mmol), yield 57%.
The feature of compound (b) is as follows：
UVλ：289nm；
IR (KBr compressing tablets) v/cm-1：3436.3 (N-H), 3237.5 (NH2), 2956.2 (C-H), 1737.4 (C=N),
1531.7 (C=C)；
1H-NMR(DMSO-d6)δ：1.69(m,2H,CH2), 2.97 (s, 3H, CH3), 3.29 (m, 2H, CH2), 6.94 (s,
2H,NH2), 8.51 (s, 1H, CH), 10.92 (s, 1H, NH)；
ESI-MS：255[M+H]+。
(2) synthesis of compound 3
472mg (3.08mmol) compound (e) is dissolved in 15mL DMFs, 131mg is sequentially added
Obtained compound (b) and 15mg in (5.47mmol) sodium hydride (NaH), 260mg (1.02mmol) step (1)
(0.12mmol) dimethyl aminopyridine solid, all dissolving after under argon gas protection in 27 DEG C of environment stirring reactions 5 hours.Instead
The glacial acetic acid aqueous solution is added after should terminating to neutralize excessive sodium hydride to pH value of solution=7, saturated ammonium chloride and second is then added
Acetoacetic ester is 1 according to volume ratio:The mixed liquor of 1 composition is extracted, and the ethyl acetate layer after extraction is washed with deionized 2 again
Secondary, vacuum drying obtains the crude product of compound 3.Crude product purified by silica gel column chromatography is purified, eluant, eluent is methanol and dichloro
Methane, using the method for gradient elution, from ethanol/methylene (v/v) 1:50 gradually become 1:10, obtain compound 3
168mg (0.59mmol), yield 58%.
The feature of compound 3 is as follows：
UVλ：272nm；
IR (KBr compressing tablets) v/cm-1：3339.1 (N-H), 1671.4 (C=C), 1474.5 (C=N), 1262.6 (C-O-C)；
1H-NMR(DMSO-d6)δ：5.27(s,2H,CH2), 6.23 (s, 2H, NH2), 7.56-8.11 (m, 4H, C6H4),
8.76 (s, 1H, CH), 11.47 (s, 1H, NH)；
ESI-MS：287[M+H]+。
The tumour cell AGT protein inhibitor activity ratings of embodiment 7
1st, experiment material and instrument
Test compound：Obtained compound 1,2,3 in above-described embodiment 1-6；
Cell line：Nasopharyngeal carcinoma cell KB, human cervical carcinoma cell HelaS3, human brain neuroglial cytoma SF763, people prostatitis
Adenocarcinoma cell DU145, human colon cancer cell HT29 and lymphoma cell Raji.
2nd, experimental method
Six kinds of tumour cells are inoculated with 96 orifice plates with 1000/ hole respectively, in 37 DEG C, 5%CO2After culture 24 hours, change to be
The BCNU (positive controls) of row concentration (1 μM, 5 μM, 10 μM, 50 μM, 100 μM, 200 μM, 400 μM and 1000 μM), card
Mo Siting (BCNU)+compound 1, BCNU+ compounds 2, BCNU+ compounds 3, every group of 5 multiple holes, and blank control group is set.
By above-mentioned each group respectively under normal oxygen and hypoxia condition effect (oxygen content is about 21% under the conditions of normal oxygen, hypoxemia bar within 48 hours
1%) oxygen content is about under part.Then, to every μ L CCK-8 solution of Kong Zhongjia 10, act on 4 hours.Finally, determine in 450nm
The absorbance at place, calculates cytoactive, and obtain half inhibiting rate IC by regression analysis calculating as follows50。
Tumor cell survival (%)=(ADosing group–ABlank group)/(AControl group–ABlank group)×100
ADosing groupFor the absorbance in the hole with tumour cell, CCK-8 solution and drug solution (BCNU+ compounds 1/2/3)；
ABlank groupFor with culture medium and CCK-8 solution without the absorbance in the hole of tumour cell；
AControl groupFor with tumour cell, CCK-8 solution without the absorbance in the hole of drug solution.
3rd, experimental result：It is shown in Table 1.
Half inhibiting rate (the IC of the tumour cell of table 150, μM)
The result of table 1 is shown, under normal oxygen environment, compared with positive controls (BCNU groups), BCNU+ compounds 1,2 or 3 pair six
Plant the IC of tumour cell50Value is basically identical, shows that AGT is active in compound 1,2 and 3 pairs of six kinds of tumour cells under normal oxygen environment
Inhibitory action it is very weak.
Under low-oxygen environment, compared with positive controls (BCNU groups), BCNU+ compounds 1,2 or 3 pairs of six kinds of tumour cells
IC50Value substantially reduction, shows that compound 1,2 and 3 can generate O by specific reduction under low-oxygen environment6- benzyl guanine class
Like thing to suppress as AGT, so as to effectively inhibit tumour cell AGT activity, tumour cell is enhanced to the quick of chemotherapeutics
Perception.
Contrast the IC of BCNU+ compounds 1,2 or 3 under normal oxygen and low-oxygen environment50Value, it can be seen that low-oxygen environment is than normal oxygen ring
The inhibiting tumour cells activity of medicine is increased significantly under border, shows that compound 1,2 and 3 can be selectively in low-oxygen environment
In be activated, so as to play AGT inhibitory action.Therefore, compound 1,2 and 3 can suppress to be under low-oxygen environment with specific
Solid tumor cell AGT activity；The AGT activity in the normal cell under normal oxygen environment is not influenceed simultaneously so that normal
Cell from chemotherapeutics damage, so as to reach chemotherapeutics targeting in the purpose of tumour cell.
Result above shows that compound provided by the present invention is under the conditions of normal oxygen without obvious AGT inhibitory action.But
It is that the AGT activity in tumour cell can be significantly inhibited under low-oxygen environment, and than existing AGT inhibitor O6- benzyl bird is fast
Purine has the tumour cell targeting of stronger AGT inhibitory activity, more highly-water-soluble and hypoxemia activation.Therefore, the present invention is carried
The compound of confession can be used for the adjuvant of alkylating agents chemotherapy medicine, and tumour cell is being improved to chemotherapy drug susceptibility to realize
Simultaneously so that act on tumour cell to chemotherapeutics targeting, so as to improve the chemotherapy effect of medicine.
Although above the present invention is described in detail with a general description of the specific embodiments,
On the basis of the present invention, it can be made some modifications or improvements, this will be apparent to those skilled in the art.Cause
This, these modifications or improvements, belong to the scope of protection of present invention without departing from theon the basis of the spirit of the present invention.
Claims (10)
1. a kind of AGT protein inhibitors for being used to prepare antineoplastic, wherein the tumour refers to nasopharyngeal carcinoma cell KB, Ren Gong
Neck cancer cell HelaS3, human brain neuroglial cytoma SF763, Human Prostate Cancer Cells DU145, human colon cancer cell HT29 are thin
Born of the same parents and lymphoma cell Raji, it is characterised in that the inhibitor is：
2. the preparation method of inhibitor described in claim 1, it is characterised in that comprise the following steps：
1) 2- amido-6-chloropurines and 1- crassitudes reaction generation compound (b)；
2) formula (II) compound and compound (b) the reaction generation inhibitor；
Wherein, the structural formula of compound (b) is as follows：
The general structure of formula (II) compound is as follows, and nitro is located at ortho position or meta：
3. method according to claim 2, it is characterised in that step 1) be specially：2- amido-6-chloropurines, which are dissolved in, to be had
Machine solvent, adds 1- crassitudes, and stirring reaction, reaction generation compound (b), reaction terminates to add acetone in backward solution
And continue stirring to compound (b) precipitation completely, filter and by the solid being collected into, washed with ether 2 times, be dried in vacuo, obtain
To dry compound (b).
4. method according to claim 3, it is characterised in that step 1) in 2- amido-6-chloropurines and 1- methylpyrroles
The mol ratio of alkane is 1:1-4；The organic solvent be DMF or dimethyl sulfoxide (DMSO), consumption of organic solvent be by
2- amido-6-chloropurines 1mmol is counted, and uses organic solvent 10-15mL；Reaction temperature is controlled at 20-40 DEG C；Reaction time is
12-24 hours.
5. method according to claim 4, it is characterised in that step 1) in 2- amido-6-chloropurines and 1- methylpyrroles
The mol ratio of alkane is 1:2-3；The organic solvent is N,N-dimethylformamide；Reaction temperature is controlled at 25-35 DEG C；During reaction
Between be 16-20 hours.
6. method according to claim 2, it is characterised in that step 2) be specially：Formula (II) compound is dissolved in organic
In solvent, step 1 is added) obtained compound (b), sodium hydride and dimethyl aminopyridine, are stirred under inert gas shielding
Reaction, reaction adds the glacial acetic acid aqueous solution to neutralize excessive sodium hydride to pH value of solution=7 after terminating, then add saturation chlorination
Ammonium and ethyl acetate by volume 1：The mixed liquor of 1 composition is extracted, and the ethyl acetate layer after extraction is washed with deionized water again
Wash 2 times, be dried in vacuo, obtain the crude product of formula (I) compound, crude product purified by silica gel column chromatography is purified, produce the suppression
Preparation.
7. method according to claim 6, it is characterised in that step 2) in dimethylamino naphthyridine, compound (b), formula
(II) compound and the mol ratio of sodium hydride are 1:6-12:10-50:30-60；The organic solvent is N,N-dimethylformamide
Or dimethyl sulfoxide (DMSO), consumption of organic solvent is based on compound (b) 1mmol, to use organic solvent 10-15mL；Reaction temperature control
System is at 20-35 DEG C；Reaction time is 3-6 hours.
8. method according to claim 7, it is characterised in that step 2) in dimethylamino naphthyridine, compound (b), formula
(II) compound and the mol ratio of sodium hydride are 1:8-10:20-30:40-50；The organic solvent is N, N- dimethyl formyls
Amine；Reaction temperature is controlled at 25-30 DEG C；Reaction time is 4-5 hours.
9. method according to claim 6, it is characterised in that step 2) in silica gel column chromatography elution used when purifying
Agent is the mixed liquor of methanol and dichloromethane, using the method for gradient elution, the volume ratio of methanol and dichloromethane in mixed liquor
By 1:50 gradually become 1:10.
Application of the 10.AGT protein inhibitors in antineoplastic is prepared, wherein, the tumour refers to nasopharyngeal carcinoma cell KB, people
Cervical cancer cell HelaS3, human brain neuroglial cytoma SF763, Human Prostate Cancer Cells DU145, human colon cancer cell HT29
Cell and lymphoma cell Raji；The inhibitor is with as led to the compound shown in formula (I) structure：
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510674275.8A CN105367573B (en) | 2015-10-16 | 2015-10-16 | AGT protein inhibitors, its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510674275.8A CN105367573B (en) | 2015-10-16 | 2015-10-16 | AGT protein inhibitors, its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105367573A CN105367573A (en) | 2016-03-02 |
| CN105367573B true CN105367573B (en) | 2017-07-14 |
Family
ID=55370258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510674275.8A Expired - Fee Related CN105367573B (en) | 2015-10-16 | 2015-10-16 | AGT protein inhibitors, its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105367573B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107235981B (en) * | 2017-05-25 | 2019-10-25 | 北京工业大学 | Hypoxemia activates O6- benzyl -2- nitro purine derivative and preparation method and application |
| CN111467500B (en) * | 2020-03-23 | 2022-08-09 | 北京工业大学 | Low-oxygen dual-targeting AGT inhibitor conjugate and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1720332A (en) * | 2002-10-03 | 2006-01-11 | 洛桑生态综合技术联合公司 | Substrates for O6-alkylguanine-DNA alkyltransferase |
| CN104844710A (en) * | 2015-04-13 | 2015-08-19 | 西北大学 | Preparation method and applications of oriented immobilized PEGA composite resin |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7825096B2 (en) * | 2004-09-08 | 2010-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | O6-alkylguanine-DNA alkyltransferase inactivators and beta-glucuronidase cleavable prodrugs |
-
2015
- 2015-10-16 CN CN201510674275.8A patent/CN105367573B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1720332A (en) * | 2002-10-03 | 2006-01-11 | 洛桑生态综合技术联合公司 | Substrates for O6-alkylguanine-DNA alkyltransferase |
| CN104844710A (en) * | 2015-04-13 | 2015-08-19 | 西北大学 | Preparation method and applications of oriented immobilized PEGA composite resin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105367573A (en) | 2016-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2881395B1 (en) | Piperazinotriazole compound, preparation method therefor, and use thereof in drug preparation | |
| CN104812389A (en) | Certain chemical entities, compositions, and methods | |
| CN104507931A (en) | New compounds | |
| WO2009043223A1 (en) | The chiral ruthenium complexes and their use as anti-tumor drug | |
| CN101624376B (en) | Substituted hydrazide compound and application thereof | |
| AU2020342189A1 (en) | 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof | |
| WO2022199547A1 (en) | 7,9-dihydropurine derivative and pharmaceutical purpose thereof | |
| CN105367573B (en) | AGT protein inhibitors, its preparation method and application | |
| JP6933644B2 (en) | Androgen receptor antagonist | |
| CN107567503A (en) | Prognosis biomarker for TTK inhibitor chemotherapy | |
| CN100398540C (en) | Aryl heterocyclic imidazole naphthaimide kind compound and its application | |
| KR20150058441A (en) | Means and method for treating solid tumours | |
| CN107137408A (en) | A kind of CDK4/6 inhibitor combines the purposes in the medicine for preparing treatment breast cancer with arimedex | |
| CN117024413A (en) | 3-aminopyrazine-2-formamide targeted proteolytic chimera, and preparation method, pharmaceutical composition and application thereof | |
| CZ305683B6 (en) | Asymmetric Troger bases with hydrazone group and their use in the treatment of oncologic diseases | |
| KR102025323B1 (en) | Novel ruthenium complex, preparation method thereof and Pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient | |
| KR102016699B1 (en) | Novel ruthenium complex, preparation method thereof and Pharmaceutical composition for use in preventing or treating cancer containing the same as an active ingredient | |
| CA3132640A1 (en) | Novel heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same | |
| CN103059019B (en) | Imidazoles [4,5-c] pyridine-7-carboxamides derivatives, its method for making and medicinal use | |
| CN112279863A (en) | Conjugate of Hsp90 inhibitor and camptothecin derivative as well as preparation method and application thereof | |
| CN106866684B (en) | Macrocyclic derivatives for the treatment of tumors | |
| CN103965202B (en) | Bicyclic-fused heterogeneous ring compound, Preparation Method And The Use | |
| CA2888015A1 (en) | 2',5'-dideoxy-5-fluorouridine derivatives having cytotoxic activity, a process for the manufacture thereof and application thereof | |
| WO2023093701A1 (en) | Platinum (ii) compound having targeting effect and derivative thereof, preparation method, pharmaceutical composition, and use | |
| CN104884456B (en) | PI3K and/or mTOR inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170714 Termination date: 20211016 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |